ACB: Record medical cannabis revenue and EBITDA, with focus shifting to global medical markets - Stock Watch Index

ACB: Record medical cannabis revenue and EBITDA, with focus shifting to global medical markets

June 11, 2026

Record annual medical cannabis revenue and adjusted EBITDA were achieved, driven by strong international growth and strategic acquisitions. The outlook anticipates lower revenue and EBITDA due to Canadian pricing changes, with a continued focus on global medical markets.

Original document: Aurora Cannabis Inc. [ACB] Earnings Release — Jun. 11 2026

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Canadian stocks Earnings Quartr

© AI-generated summary is provided by Quartr

Search

RECENT PRESS RELEASES

Lululemon backs renewable energy in China

SWI Editorial Staff2026-06-11T04:09:35-07:00June 11, 2026|

Can corporate backers give emerging VC funds an edge?

SWI Editorial Staff2026-06-11T04:08:06-07:00June 11, 2026|

Big tech is preventing new stock-market highs due to the changing way investors play the A

SWI Editorial Staff2026-06-11T04:07:00-07:00June 11, 2026|

Is Bitcoin Going to $0? Here’s the Honest Answer.

SWI Editorial Staff2026-06-11T04:07:00-07:00June 11, 2026|

Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹

SWI Editorial Staff2026-06-11T04:05:00-07:00June 11, 2026|

GM letting some EV owners sell electricity back to the US power grid

SWI Editorial Staff2026-06-11T04:00:43-07:00June 11, 2026|

Related Post